SCHEMBL5465340

SCHEMBL5465340

COc1ccc(-c2ccnc(NC(=O)c3cccs3)n2)cc1OC

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.61
SMN1; SMN2 Q16637 4/20 0.61
GAA P10253 3/20 0.61
NPC1 O15118 2/20 0.61
RAB9A P51151 2/20 0.61
MAPT P10636 8/20 0.58
KMT2A Q03164 6/20 0.58
MEN1 O00255 5/20 0.58
LMNA P02545 4/20 0.58
POLB P06746 3/20 0.58
MCL1 Q07820 1/20 0.58
KDM4E B2RXH2 1/20 0.55
HPGD P15428 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.54
PKM P14618 1/20 0.54
HDAC1 Q13547 1/20 0.53
ABL1 P00519 1/20 0.52
PDGFRB P09619 1/20 0.52
SRC P12931 1/20 0.52
PDGFRA P16234 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5465964 0.86 RAB9A (0.60) ALDH1A1SMN1; SMN2GAANPC1RAB9A
SCHEMBL5472432 0.86 RAB9A (0.65) ALDH1A1SMN1; SMN2GAANPC1RAB9A
SCHEMBL5465088 0.83 RAB9A (0.59) ALDH1A1SMN1; SMN2GAANPC1RAB9A
SCHEMBL5466020 0.82 RAB9A (0.67) ALDH1A1SMN1; SMN2GAANPC1RAB9A
SCHEMBL5465855 0.82 HDAC1 (0.67) ALDH1A1SMN1; SMN2MAPTKMT2AMEN1
SCHEMBL5473477 0.82 NPC1 (0.70) ALDH1A1SMN1; SMN2GAANPC1RAB9A
SCHEMBL4003528 0.81 ABL1 (0.58) ALDH1A1SMN1; SMN2GAANPC1RAB9A
SCHEMBL5472912 0.81 RAB9A (0.74) ALDH1A1SMN1; SMN2GAANPC1RAB9A
SCHEMBL5467105 0.80 RAB9A (0.70) ALDH1A1SMN1; SMN2GAANPC1RAB9A
SCHEMBL5465929 0.80 NPC1 (0.70) ALDH1A1SMN1; SMN2GAANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070099938-A1 Antistress drug and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-05-03 US disclosed
EP-1679309-A1 ANTISTRESS DRUG AND MEDICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099938-A1 Antistress drug and medical use thereof NPSR1, MC2R, SRR ALDH1A1 2447/4885SMN1; SMN2 2306/4885GAA 3044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.